net_left Kdata adver left
Detail

In China, no easy way to get Pfizer's COVID drug Paxlovid

By Sophie Yu and Martin Quin Pollard BEIJING (Reuters) - When Li's 83-year-old father with diabetes started coughing and complaining of body aches last month, the Beijing resident...
In China, no easy way to get Pfizer's COVID drug Paxlovid © Reuters. FILE PHOTO: Weng Shuiye, a 77-year-old receives oxygen at a hospital, amid the coronavirus disease (COVID-19) outbreak, at a village in Tonglu county, Zhejiang province, China January 9, 2023. REUTERS/Staff
let atwWrapper,atwContainerWidth,atwSliderBox,atwTotalWidth; function initATWSlider() { atwWrapper = $('.relatedInstruments'); atwSliderBox = atwWrapper.find('.slider'); atwContainerWidth = atwWrapper.width(); atwTotalWidth = atwSliderBox.width(); if(window.domainId === '2' || window.domainId === '3'){ atwWrapper.find('.sliderRight').addClass('js-slider-prev'); atwWrapper.find('.sliderLeft').addClass('js-slider-next'); } else { atwWrapper.find('.sliderRight').addClass('js-slider-next'); atwWrapper.find('.sliderLeft').addClass('js-slider-prev'); } if(atwSliderBox.find('.instrumentBox').length > 6){ atwWrapper.find('.js-slider-next').fadeIn(600); } } function atwMoveRight() { atwWrapper.find('.js-slider-prev').fadeIn(150); $(".slider > :visible:first").hide(150) $(".slider > :visible:last").next().show(150); if(!$(".slider > :visible:last").next().find('.name')()){ atwWrapper.find('.js-slider-next').fadeOut(150); return; } } function atwMoveLeft() { atwWrapper.find('.js-slider-next').fadeIn(150); $(".slider > :visible:last").hide(150); $(".slider > :visible:first").prev().show(150); if(!$(".slider > :visible:first").prev().find('.name')()){ atwWrapper.find('.js-slider-prev').fadeOut(150); return; } } initATWSlider(); //update star icon on adding/removing instrument to/from specific watchlist atwWrapper.on('click', 'label.addRow', function() { let parent = $(this).parent(); let checkedPortfolio = false; parent.find('input[type=checkbox]').each(function () { if($(this).is(':checked')){ checkedPortfolio = true; } }); let closestStar = $(this).closest('.addToPortWrapper').find('.star'); if(checkedPortfolio){ closestStar.addClass('added'); }else{ closestStar.removeClass('added'); } }); //update star icon on creating new watchlist atwWrapper.find('.js-create-watchlist-portfolio').find('a.js-create').on('click',function () { let parent = $(this).parent(); let watchlistName = parent.find('input[type=text]').val(); if(!watchlistName){ return; } let star = $(this).closest('.addToPortWrapper').find('.star'); star.addClass('added'); }); //update star icon on adding new position atwWrapper.find('.js-create-holdings-portfolio').find('.js-submit').on('click',function () { let addPositionForm = $(this).closest('.addToPortfolioPop').find('.holdingsContent'); let amount = addPositionForm.find('.js-amount').val(); if(amount < 1){ return; } let star = $(this).closest('.addToPortWrapper').find('.star'); star.addClass('added'); }); atwWrapper.find('.instrumentBox').find('.shortInfo').on('click',function () { if(!window.ga){ return; } let pairId = $(this).parent().find('.js-add-to-portfolio').attr('data-pair-id'); let pairType = window.atwPairTypes[pairId]; window.ga('allSitesTracker.send', 'event', 'content', 'symbol link clicked', '', { "dimension147":"symbol_link_clicked", "dimension163":"click", "dimension148":"symbol", "dimension162":"content add to watchlist", "dimension161":"article page", "dimension142":"article", "dimension75":pairType, "dimension138":pairId, "dimension118":"2980690" }); window.open($(this).attr('data-href')); }); window.atwPairTypes = {"2111":"currency","7989":"Equities"};

By Sophie Yu and Martin Quin Pollard

BEIJING (Reuters) - When Li's 83-year-old father with diabetes started coughing and complaining of body aches last month, the Beijing resident became anxious about finding a treatment for COVID-19 in case his parent had caught the virus sweeping the city.

He heard at that time that Pfizer (NYSE:PFE)'s anti-viral drug Paxlovid was an effective treatment, but patients could only get it prescribed if they were admitted to hospital, and only if the drug was in stock.

The first hospital they visited conducted a CT scan that showed his lungs were infected, but turned them away, saying no beds were available, said Li, who only gave his surname due to sensitivity over how authorities might view his account.

After two more days of frantic calls to families and friends, a contact finally found them a space at another hospital, but it took a further antigen test and second CT scan before it agreed to prescribe the drug.

With his father admitted to an intensive care unit, Li was worried that it had taken too long to get effective treatment.

"I’m not sure if Paxlovid can help him. I think it's because when he got the medicine he already had the virus for a week," Li told Reuters on Jan.12.

"Now we can do little but pray."

His father died the same day.

Li's experience, local media reports and online posts bear testimony to the difficulties faced obtaining Paxlovid in China through official channels.

Paxlovid - a combination of two anti viral drugs - is one of the few foreign oral treatments approved by Beijing and a clinical trial has found it to have reduced hospitalisations in high-risk patients by around 90%.

Having been approved in February last year, Paxlovid was scarcely used in China until December when the government started lifting its strict containment policy, and wave of COVID infections began to build.

RAMPING UP SUPPLIES

Chinese authorities have acknowledged that supplies of Paxlovid are still insufficient to meet demand, even as Pfizer CEO Albert Bourla said last week that thousands of courses of the treatment were shipped to the country last year and in the past couple of weeks millions more were shipped.

"Pfizer is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China. We remain committed to fulfilling the COVID-19 treatment needs of Chinese patients and partnering with the Chinese government," the company said in a statement.

Racing to defend against a rising death toll, China has also approved Merck & Co's COVID antiviral drug and is reviewing a treatment developed by Japan's Shionogi.

Paxlovid is covered by state insurance -- albeit temporarily until the end of March -- meaning patients in theory would only need to pay 198 yuan ($29), a tenth of its usual price.

But China doesn't provide data on how many treatment courses are supplied and where it can be purchased, forcing most patients to rely on media reports, word-of-mouth or even importing through unauthorised channels in the grey market.

Those who do manage to find a supplier often end up paying exorbitant prices, as demand has shot up amid a giant wave of COVID-19 infections.

The official Guangzhou Daily reported that patients at the United Family Healthcare hospital in Guangdong were paying 6,000 yuan ($891) for health checks before being allowed to get Paxlovid priced at 2,300 yuan at the hospital.

The hospital did not immediately reply to a Reuters' request for comment.

Health data firm Airfinity estimated in December that China would need 49 million courses of the COVID treatment over the next five months, with over 22 million needed in January alone.

The Pfizer drug can be also purchased for 2,170 yuan with prescription via online platforms, but it typically sells out within seconds.

PAXLOVID GIFT

Several other people described to Reuters how they turned to the grey market to purchase Paxlovid. Some were looking to treat sick relatives, while others wanted it just in case.

Chen Jun, a resident of China's southern Hainan Province, said he bought Paxlovid from a supplier introduced by a business partner, who said the medicine was coming from Hong Kong.

Chen paid 20,000 yuan ($2,972) on Jan. 2 for two boxes for his elderly parents, who suffer from cancer, and he said that some people had paid double that price.

"You'll think it cheap once your family members are in need, because anything is better than going to a hospital now," he said. "I know people who paid 20,000 yuan for one box of the medicine."

Another buyer who gave his name as Ray said he managed to get two boxes from the United States, where supplies are still ample and a doctor's prescription can be obtained after an online consultation.

"It's very straightforward, they don't ask questions," he said. Having made the online purchase, he then asked a friend there to help courier it to China.

An analyst at a Chinese securities house, who requested anonymity because of sensitivities over the subject, said his boss went to Hong Kong to stock up on Paxlovid to gift clients as it was more valued than a popular, expensive liquor.

"It is a better gift than Moutai."

($1 = 6.7072 Chinese yuan renminbi)

HOT AUTO TRADE BOT SOFTWARE adver right
APPROVED BROKERS
net_home_top HOT AUTO TRADE BOT SOFTWARE
21-02-2024 10:47:15 (UTC+7)

EUR/USD

1.0815

+0.0012 (+0.11%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (5)

Sell (0)

EUR/USD

1.0815

+0.0012 (+0.11%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (5)

Sell (0)

GBP/USD

1.2633

+0.0015 (+0.12%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (1)

USD/JPY

149.91

-0.07 (-0.05%)

Summary

Neutral

Moving Avg:

Buy (7)

Sell (5)

Indicators:

Buy (2)

Sell (3)

AUD/USD

0.6570

+0.0022 (+0.33%)

Summary

Buy

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (7)

Sell (2)

USD/CAD

1.3510

-0.0010 (-0.07%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (6)

EUR/JPY

162.14

0.01 (0.00%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (4)

Sell (1)

EUR/CHF

0.9527

-0.0006 (-0.06%)

Summary

Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (2)

Sell (5)

Gold Futures

2,041.05

+1.25 (+0.06%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (4)

Sell (2)

Silver Futures

23.200

+0.064 (+0.28%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (8)

Sell (0)

Copper Futures

3.8732

+0.0154 (+0.40%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (0)

Crude Oil WTI Futures

77.30

+0.26 (+0.34%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (1)

Sell (7)

Brent Oil Futures

82.65

+0.31 (+0.38%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (1)

Sell (6)

Natural Gas Futures

1.702

-0.006 (-0.35%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (1)

Sell (9)

US Coffee C Futures

188.03

+1.33 (+0.71%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (0)

Euro Stoxx 50

4,759.75

-3.32 (-0.07%)

Summary

↑ Sell

Moving Avg:

Buy (3)

Sell (9)

Indicators:

Buy (0)

Sell (8)

S&P 500

4,975.51

-30.06 (-0.60%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (1)

DAX

17,068.43

-23.83 (-0.14%)

Summary

Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (1)

Sell (5)

FTSE 100

7,719.21

-9.29 (-0.12%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (9)

Sell (0)

Hang Seng

16,727.00

+479.49 (+2.95%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

US Small Cap 2000

2,003.65

-29.09 (-1.43%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

IBEX 35

10,038.20

+93.40 (+0.94%)

Summary

Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (0)

Sell (5)

BASF SE NA O.N.

46.045

+0.270 (+0.59%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (8)

Bayer AG NA

28.77

-0.14 (-0.47%)

Summary

Neutral

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (3)

Sell (3)

Allianz SE VNA O.N.

249.40

+0.75 (+0.30%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (1)

Sell (7)

Adidas AG

181.12

+1.40 (+0.78%)

Summary

↑ Buy

Moving Avg:

Buy (9)

Sell (3)

Indicators:

Buy (9)

Sell (1)

Deutsche Lufthansa AG

7.339

+0.002 (+0.03%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

Siemens AG Class N

168.72

-0.86 (-0.51%)

Summary

Neutral

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (3)

Sell (5)

Deutsche Bank AG

11.954

-0.042 (-0.35%)

Summary

↑ Sell

Moving Avg:

Buy (3)

Sell (9)

Indicators:

Buy (0)

Sell (9)

    EUR/USD 1.0815 ↑ Buy  
    GBP/USD 1.2633 ↑ Buy  
    USD/JPY 149.91 Neutral  
    AUD/USD 0.6570 Buy  
    USD/CAD 1.3510 ↑ Sell  
    EUR/JPY 162.14 Neutral  
    EUR/CHF 0.9527 Sell  
    Gold 2,041.05 Buy  
    Silver 23.200 ↑ Buy  
    Copper 3.8732 ↑ Buy  
    Crude Oil WTI 77.30 ↑ Sell  
    Brent Oil 82.65 Sell  
    Natural Gas 1.702 ↑ Sell  
    US Coffee C 188.03 ↑ Buy  
    Euro Stoxx 50 4,759.75 ↑ Sell  
    S&P 500 4,975.51 ↑ Buy  
    DAX 17,068.43 Sell  
    FTSE 100 7,719.21 ↑ Buy  
    Hang Seng 16,727.00 ↑ Buy  
    Small Cap 2000 2,003.65 ↑ Buy  
    IBEX 35 10,038.20 Sell  
    BASF 46.045 ↑ Sell  
    Bayer 28.77 Neutral  
    Allianz 249.40 Sell  
    Adidas 181.12 ↑ Buy  
    Lufthansa 7.339 ↑ Buy  
    Siemens AG 168.72 Neutral  
    Deutsche Bank AG 11.954 ↑ Sell  
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank7,650/ 7,820
(100/ 70) # 1,784
SJC HCM7,630/ 7,850
(40/ 30) # 1,814
SJC Hanoi7,630/ 7,852
(40/ 30) # 1,816
SJC Danang7,630/ 7,852
(40/ 30) # 1,816
SJC Nhatrang7,630/ 7,852
(40/ 30) # 1,816
SJC Cantho7,630/ 7,852
(40/ 30) # 1,816
Cập nhật 21-02-2024 10:47:17
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$2,029.99 +13.55 0.67%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩm Vùng 1 Vùng 2
RON 95-V24.95025.440
RON 95-III24.16024.640
E5 RON 92-II22.91023.360
DO 0.05S20.99021.400
DO 0,001S-V21.97022.400
Dầu hỏa 2-K20.92021.330
ↂ Giá dầu thô thế giới
WTI $77.24 +3.43 0.05%
Brent $81.97 +3.26 0.04%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD24.310,0024.680,00
EUR25.830,1527.248,00
GBP30.162,2431.446,11
JPY158,58167,85
KRW15,8919,26
Cập nhật lúc 10:40:19 21/02/2024
Xem bảng tỷ giá hối đoái
adver main right